VSTM

Verastem, Inc.

12.07 USD
+0.46 (+3.96%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Verastem, Inc. stock is up 23.92% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 53.85% of the previous 12 May’s closed higher than April. 100% of analysts rate it a buy.

About Verastem, Inc.

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.